Eyetech's Macugen Approved in Canada

May 9, 2005

Health Canada has granted approval (Notice of Compliance) for Macugen (pegaptanib sodium injection) of Eyetech Pharmaceuticals for the treatment of subfoveal choroidal neovascularization (CNV) secondary to neovascular age-related macular degeneration (neovascular AMD). Macugen is the first therapy indicated in Canada for the treatment of subfoveal neovascular AMD regardless of lesion subtype or size.

Pharmabiz (http://www.pharmabiz.com/article/detnews.asp?articleid=27500§ionid=)